← feed

Is NCT01857193 results overdue?

Yes — results are overdue. Primary completion was 2018-03-14; the FDAAA-801 reporting deadline (2019-03-14) passed 2702 days ago and no results are posted on ClinicalTrials.gov.

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

NCT IDNCT01857193 ↗
SponsorNovartis Pharmaceuticals (INDUSTRY)
Public issuerNOVARTIS AG — NVS (CIK 0001114448) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-03-14 (ACTUAL)
Reporting deadline2019-03-14 (completion + 365d)
Days overdue2702
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 9bea6f7f9ba118fb… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT01857193. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →